ERBB2 and breast carcinoma: The MONALEESA-2 trial, a phase III randomized double-blind study, evaluated ribociclib + letrozole versus placebo + letrozole in 668 treatment-naïve postmenopausal women with HR+/HER2- advanced breast cancer.